Cullinan Therapeutics (CGEM) Q3 2026 earnings summary

Executive summary

• Clinical and regulatory programs advanced across autoimmune disease and oncology, with multiple data presentations and study milestones planned for late 2026.

• Cash, investments and interest receivable totaled $313.8M at September 30, 2026; the current operating plan projects runway into 2029.

• Q3 net loss was $49.4M.

Financial highlights

• Q3 2026 R&D expense was $40.2M vs. $42.0M a year earlier; G&A was $12.4M vs. $13.6M, and total operating expenses were $52.6M vs. $55.6M.

• Q3 net loss was $49.4M vs. $50.6M; nine-month net loss was $152.8M vs. $169.2M.

• Nine-month operating cash use was $127.3M vs. $137.6M; investing activities provided $124.7M, primarily from marketable security maturities.

• Nine-month R&D expense declined $17.7M year over year, mainly reflecting the prior-year $20.0M velinotamig license fee, partly offset by $6.6M higher clinical development costs.

Outlook and guidance

• December CLN-978 update planned: multi-dose data across SLE, RA and Sjögren’s disease, clinical activity, biomarkers and safety, plus longer follow-up and initial Sjögren’s data.

• Updated CLN-049 Phase 1 dose-escalation data scheduled for the December 13, 2026 ASH Annual Meeting.

• Completion of the zipalertinib first-line combination NDA submission expected in November 2026; monotherapy NDA action date is February 27, 2027.

• Current operating plan supports runway into 2029; expenses are expected to rise with trials, preclinical work, manufacturing, regulatory submissions, hiring and potential pipeline expansion.